In vitro studies showed that resistance to EGFR and HER2 inhibitors is, in part, attributed to cytoprotective autophagy, and that inhibiting this process with genetic or pharmacological inhibitors, such as hydroxychloroquine (HCQ), promotes the sensitization of breast cancer cells to treatments [20,22]. The gene discussed is EGFR; the disease is breast carcinoma.